Xenetic Biosciences, Inc. (XBIO) shareholders
Close on Nov 17, 2026Market cap $3.77MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Dmitry Genkin Joint filing with CLS Therapeutics Ltd. (9.60%), Victor Tets (9.60%) and 2 more | 215,964 | – | 13D (active) amendment | Mar 18, 2024 |
| Renaissance Technologies LLC Joint filing with Renaissance Technologies Holdings Corporation (6.00%) | 137,440 | 6.00% | 13G (passive) amendment | Mar 31, 2026 |
| Michael Liu | 126,741 | 5.50% | 13G (passive) | May 22, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 117,440 | 5.01% | $341.75K | −20,000 | 0.00% |
| Geode Capital Management, LLC | 17,423 | 0.74% | $50.72K | −4,018 | 0.00% |
| Vanguard Capital Management LLC | 12,681 | 0.54% | $36.90K | +5,950 | 0.00% |
| JTC Employer Solutions Trustee Ltd | 2,700 | 0.12% | $8.00K | – | 0.00% |
| SBI Securities Co., Ltd. | 1,000 | 0.04% | $2.91K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 696 | 0.03% | $2.03K | −110 | 0.00% |
| Morgan Stanley | 150 | 0.01% | $437 | New | 0.00% |
| Darwin Wealth Management, LLC | 2 | 0.00% | $5 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 6.5% | 2 / 1 | 3 / 0 | 0M | 0M |
| Q1 2026 | 6 | 0M | 7.2% | 1 / 1 | 2 / 6 | 0M | 0M |
| Q4 2025 | 11 | 0M | 9.8% | 4 / 3 | 1 / 3 | 0M | 0M |
| Q3 2025 | 10 | 0M | 2.5% | 2 / 2 | 1 / 1 | 0M | 0M |
| Q2 2025 | 9 | 0M | 2.7% | 0 / 2 | 2 / 4 | 0M | 0M |
| Q1 2025 | 13 | 0M | 4.6% | 1 / 6 | 1 / 1 | 0M | 0M |
| Q4 2024 | 13 | 0M | 3.8% | 6 / 1 | 2 / 2 | 0M | 0M |
| Q3 2024 | 9 | 0M | 2.1% | 5 / 1 | 1 / 1 | 0M | 0M |
| Q2 2024 | 5 | 0M | 0.6% | 1 / 1 | 2 / 3 | 0M | 0M |
| Q1 2024 | 7 | 0M | 0.8% | 0 / 2 | 1 / 0 | 0M | 0M |
| Q4 2023 | 7 | 0M | 0.7% | 1 / 1 | 2 / 1 | 0M | 0M |
| Q3 2023 | 7 | 0M | 0.7% | 1 / 1 | 2 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held XBIO in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of XBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 13,725 | 0.59% | $42.82K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 12,681 | 0.54% | $36.90K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,070 | 0.09% | $6.46K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 1,388 | 0.06% | $4.33K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| James F. Parslow | Interim CEO and CFO | 100,000 | 4.27% | Apr 23, 2026 |
| Roger D. Kornberg | Director | 0 | – | Jan 5, 2026 |
| Firdaus J. Dastoor | Director | – | – | Jan 5, 2026 |
| Grigory G. Borisenko | Director | – | – | Jan 5, 2026 |
| Alexey Andreevich Vinogradov | Director | 186,781 | 7.97% | Jan 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James F. Parslow Interim CEO and CFO | Apr 21, 2026 | Award | +100,000 | – | – | 100,000 |
| Dmitry Genkin Director | Jul 19, 2019 | Award | +93,390 | – | – | 93,603 |
| Dmitry Genkin Director | Mar 14, 2018 | Other | −29,452 | – | – | 2,549 |
| Jeffrey F. Eisenberg CEO, Director | Oct 26, 2017 | Award | +50,000 | – | – | 50,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Xenetic Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,735 shares on Sep 18, 2026 over the last 90 days.
See a number that looks wrong?